GlassScriptPhysician profile
Melissa K Wester
NPI 1669443941
$6,203.77
in general payments reported to CMS, 2019-2025
54 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $553 · 2021: $1,391 · 2022: $1,230 · 2023: $1,112 · 2024: $734 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,040.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,322.31 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $747.30 | 2019-2024 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $398.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $368.63 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $352.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Teva Pharmaceuticals USA, INC. | $226.24 | 2019-2023 | Ajovy |
| Antares Pharma, INC. | $183.95 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Otsuka America Pharmaceutical, INC. | $179.61 | 2021-2024 | Rexulti |
| Clarus Therapeutics INC. | $150.59 | 2021 | |
| Abbott Laboratories | $150.01 | 2021-2023 | Freestyle Libre 2 |
| Eisai INC. | $136.65 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.97 | 2022 | |
| Esperion Therapeutics, INC. | $110.92 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $108.84 | 2021 | |
| Tolmar, INC. | $106.83 | 2023-2024 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Wester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.